Published in Antimicrob Agents Chemother on July 01, 2003
Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Res (2010) 1.09
Treatment of yellow fever virus with an adenovirus-vectored interferon, DEF201, in a hamster model. Antimicrob Agents Chemother (2011) 1.07
NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. Int J Oncol (2014) 1.01
Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin. PLoS One (2010) 0.95
Host-directed Inhibitors of Myxoviruses: Synthesis and in vitro Biochemical Evaluation. ACS Med Chem Lett (2011) 0.95
Effects of interferon, ribavirin, and iminosugar derivatives on cells persistently infected with noncytopathic bovine viral diarrhea virus. Antimicrob Agents Chemother (2004) 0.88
Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A. Antimicrob Agents Chemother (2013) 0.87
Asymmetric synthesis of host-directed inhibitors of myxoviruses. Beilstein J Org Chem (2013) 0.85
Antiviral activity of Bacillus sp. isolated from the marine sponge Petromica citrina against bovine viral diarrhea virus, a surrogate model of the hepatitis C virus. Viruses (2013) 0.81
Development of one-step SYBR Green real-time RT-PCR for quantifying bovine viral diarrhea virus type-1 and its comparison with conventional RT-PCR. Virol J (2011) 0.80
Inhibition of bovine viral diarrhea virus RNA synthesis by thiosemicarbazone derived from 5,6-dimethoxy-1-indanone. J Virol (2011) 0.80
Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science (1999) 24.31
A three-dimensional model to analyze drug-drug interactions. Antiviral Res (1991) 6.58
Effect of alpha interferon on the hepatitis C virus replicon. J Virol (2001) 6.18
The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med (2000) 5.73
RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A (2001) 5.21
New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J Natl Cancer Inst (1989) 4.04
Burden of liver disease in the United States: summary of a workshop. Hepatology (2002) 4.00
Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1995) 2.49
Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J Gen Virol (2001) 2.40
Novel cell culture systems for the hepatitis C virus. Antiviral Res (2001) 2.26
Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob Agents Chemother (2003) 1.99
Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem (2001) 1.85
Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology (2002) 1.81
Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. Proc Natl Acad Sci U S A (1978) 1.79
Ribavirin causes error catastrophe during Hantaan virus replication. J Virol (2003) 1.78
Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology (1997) 1.77
Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol (1996) 1.73
Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother (2000) 1.58
Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proc Natl Acad Sci U S A (1999) 1.54
Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol (2002) 1.52
Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons. J Virol (2002) 1.51
Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J Virol (2001) 1.50
A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology (2000) 1.44
Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother (2003) 1.40
Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J Virol (2002) 1.35
Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent. Antimicrob Agents Chemother (1983) 1.33
Quasispecies, error catastrophe, and the antiviral activity of ribavirin. Virology (2002) 1.28
Mechanism of action of a pestivirus antiviral compound. Proc Natl Acad Sci U S A (2000) 1.21
Mechanisms of action of ribavirin in antiviral therapies. Antivir Chem Chemother (2001) 1.16
Analysis of combinations of antiviral drugs and design of effective multidrug therapies. Antivir Ther (1996) 1.11
Chronic viral hepatitis C: management update. CMAJ (2000) 1.10
Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res (1996) 1.06
Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses. Antimicrob Agents Chemother (1984) 0.98
Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs (2002) 0.95
Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load. Intervirology (2002) 0.82
Influence of silicone elastomer solubility and diffusivity on the in vitro release of drugs from intravaginal rings. J Control Release (2003) 0.99
Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses. Antiviral Res (2006) 0.99
In vitro release of nonoxynol-9 from silicone matrix intravaginal rings. J Control Release (2003) 0.89
A novel anti-HIV active integrase inhibitor with a favorable in vitro cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase metabolism profile. Antiviral Res (2013) 0.84
Antiviral activity of hop constituents against a series of DNA and RNA viruses. Antiviral Res (2004) 0.82
Investigation into the ability of GB virus B to replicate in various immortalized cell lines. Antiviral Res (2005) 0.80
Psychosocial impact of a positive HSV-2 diagnosis on adults with unrecognized HSV-2 infection. Public Health Nurs (2011) 0.78